<div id="readability-page-1">Microbiotica has announced positive findings from its phase 1b MELODY‑1 trial of MB097, an oral precision microbiome co‑therapy being developed for advanced melanoma.The study met all primary and secondary objectives, with the company reporting that MB097 was safely combined with pembrolizumab and showed encouraging early signs of efficacy in a population with primary resistance to anti‑PD‑1 therapy.The international trial enrolled 41 patients across the UK, France, Italy and Spain. Participants received MB097 alongside pembrolizumab for up to six months, with half also given vancomycin preconditioning to assess whether it improved bacterial engraftment. Microbiotica said the nine‑strain bacterial consortium demonstrated robust engraftment, particularly in those receiving vancomycin.Dr Pippa Corrie, National Co‑ordinating Investigator for the study, said: “There is increasing evidence that the microbiome plays a crucial role in patients’ response to immune checkpoint inhibitors. Clinical benefit has been reported with Faecal Microbiota Transplantations (FMT), while MB097 capsules taken orally each day affords an easy and reproducible way of modifying the microbiome. She added: “The MELODY‑1 study results show that MB097 is well tolerated, with encouraging early signs of efficacy in a very difficult to treat metastatic melanoma patient population with primary resistance to anti-PD-1 based immunotherapy, in whom there is a significant unmet need.”Patients benefiting at six months have entered an extension phase and may continue pembrolizumab for up to 18 additional months, with results to follow.Dr Robert Tansley, Chief Medical Officer at Microbiotica, said: “We are encouraged by these positive data on safety and engraftment. With early signs of efficacy, we look forward to further analysis from the trial respondents. “The results provide the foundation to proceed to larger controlled studies in a broader melanoma patient population and we are excited by the potential to deliver a new option to maximise patients’ potential to respond to anti-PD-1 therapy.”CEO Tim Sharpington added: “This is our second clinical trial to report positive results, following the success of our phase 1b study of MB310 in ulcerative colitis earlier this year. This is further validation of our clinic-first discovery platform and precision microbiome medicine development.”</div>

516500

159837

512290

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

BlackRock, Inc.

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Yinhua CSI Innovative Drugs Industry ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares US Pharma

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

VG Health

Direxion S&P Biotech Bull 3X

China Southern Hang Seng Biotech ETF(QDII)

SPDR S&P Biotech

VanEck Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares UltraShort Nasdaq Biotech

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Health Care Select Sector SPDR

Microbiotica reports positive results for MB097 in advanced melanoma